Shop

Philadelphia Magazine reports how "Michael Blaese left the National Institutes of Health for a Newtown biotech firm promising practical treatments from still-theoretical "gene repair." He'll succeed, or it's cold fusion all over again...His former bosses at the NIH have allocated billions of dollars for genetic research in the past decade, only to face charges that their vision of a "gene medicine" able to cure every human illness is half-baked and quixotic. Even optimistic scientists still think it will be decades before patients realize major benefits from all these studies. Blaese believes he can make it happen sooner."

This file is not available for digital download. IRE members may place an order by emailing rescntr@ire.org